Be among trailblazing marketing pros at Brandweek this September 23–26 in Phoenix, Arizona. Experience incredible networking, insightful sessions and a boost of inspiration at ADWEEK’s ultimate brand event. Register by May 13 to save 35%.
WASHINGTON — Federal regulators ordered Pfizer Inc. to stop running a print advertisement for cholesterol-lowering drug Lipitor, saying the ad’s claim that Lipitor can cut the risk of heart disease is misleading.
The Food and Drug Administration told Pfizer (PFE) that an eight-page ad for Lipitor that recently ran in a medical journal creates “an overwhelming impression” that Lipitor can reduce the risk of developing coronary heart disease.
Although Lipitor can be promoted as a cholesterol-lowering drug, it hasn’t received FDA approval as a treatment for coronary heart disease.
WORK SMARTER - LEARN, GROW AND BE INSPIRED.
Subscribe today!
To Read the Full Story Become an Adweek+ Subscriber
Already a member? Sign in